Novo Nordisk sued Eli Lilly on July 21, 2026 in the U.S. District Court for the District of New Jersey, alleging that Lilly's national GLP-1 advertising campaigns are false and misleading under the Lanham Act. Three days later, on July 24, Novo moved for a preliminary injunction to pull the ads off the air immediately rather than wait for a full trial. A court is scheduled to take up that motion on August 17.
The dispute is not about whether tirzepatide outperformed semaglutide in a trial. It did. The dispute is about which doses were on each side of that comparison — and that question matters well beyond the courtroom, because the same dose-matching problem shows up any time two compounds get ranked against each other.
Research-context information only. This article reports on pending civil litigation and published clinical trial data. Nothing here is medical or legal advice, and no allegation described below has been adjudicated. Semaglutide and tirzepatide are FDA-approved as prescription medicines; the research-use-only material sold by peptide vendors is not FDA-approved for human use and has not been evaluated for safety, purity, or potency in that channel. Consult a licensed physician for personal medical decisions.
What Novo filed
Novo's complaint targets two nationwide direct-to-consumer campaigns for Lilly's tirzepatide products, which ran during widely viewed sporting broadcasts and on TikTok and Facebook. According to Novo's July 21 announcement, the campaigns presented comparisons structured as follows:
- Tirzepatide at 10 mg and 15 mg against semaglutide at 1.7 mg and 2.4 mg
- Tirzepatide at 15 mg against the 1 mg semaglutide dose used in diabetes care, omitting the approved 2 mg dose
Novo's argument is that these pairings create the impression of a current head-to-head comparison while leaving out the higher semaglutide doses now approved in the United States. The FDA approved a 7.2 mg once-weekly semaglutide injection for obesity on March 19, 2026 — the first GLP-1 receptor agonist cleared under the agency's Commissioner's National Priority Voucher program, which returned a decision roughly 54 days after filing instead of the standard 10-to-12-month review.
Novo is seeking a permanent injunction requiring the ads to come down along with corrective advertising, plus the preliminary injunction to halt the campaigns in the interim. Lilly has disputed the allegations. Nothing has been decided; a preliminary injunction motion tests likelihood of success, not the merits themselves.
The numbers on both sides
The comparison Lilly's ads drew on is SURMOUNT-5, published in the New England Journal of Medicine in July 2025 (PMID 40353578). It is a real randomized head-to-head trial, and its result was clear.
SURMOUNT-5 randomized 751 adults with obesity and without diabetes to maximum-tolerated tirzepatide (10 or 15 mg) or maximum-tolerated semaglutide (1.7 or 2.4 mg) over 72 weeks:
| Endpoint at week 72 | Tirzepatide | Semaglutide |
|---|---|---|
| Least-squares mean weight change | −20.2% (95% CI −21.4 to −19.1) | −13.7% (95% CI −14.9 to −12.6) |
| Waist circumference change | −18.4 cm | −13.0 cm |
Tirzepatide participants were also more likely to reach reductions of at least 10%, 15%, 20%, and 25%. The trial was funded by Eli Lilly.
The dose ceiling is the pressure point. At the time SURMOUNT-5 was designed, 2.4 mg was the highest semaglutide dose approved for weight management, so capping the comparator there was a defensible design choice — not a manipulation. What changed is that the ceiling moved afterward.
The STEP UP trial (PMID 40961952), published in The Lancet Diabetes & Endocrinology in November 2025, tested that higher dose. It randomized 1,407 adults with obesity 5:1:1 to semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo for 72 weeks:
| Arm | Mean bodyweight change (treatment-policy estimand) |
|---|---|
| Semaglutide 7.2 mg | −18.7% |
| Semaglutide 2.4 mg | −15.6% |
| Placebo | −3.9% |
The estimated treatment difference between 7.2 mg and 2.4 mg was −3.1% (95% CI −4.7 to −1.6, p<0.0001). Roughly a third of the 7.2 mg group reached reductions of 25% or more. Novo's regulatory communications have cited a 20.7% figure for the same dose; that reflects a different estimand within the same program — an analysis of what happens under full adherence — rather than a separate study. The −18.7% figure is the trial's primary treatment-policy result and the more conservative of the two.
Why the cross-trial math is shakier than either side implies
Line the two trials up and semaglutide 7.2 mg (−18.7%) lands much closer to tirzepatide's SURMOUNT-5 result (−20.2%) than the 2.4 mg arm did. That is the comparison Novo's complaint gestures toward.
It is also not a head-to-head result, and there is a clean illustration of why that distinction is not pedantic. Both trials included a semaglutide 2.4 mg arm. In SURMOUNT-5 that arm lost 13.7%. In STEP UP the same dose of the same drug lost 15.6%. Same compound, same dose, 72 weeks in both cases — and a gap of nearly two percentage points, driven by differences in enrolled populations, baseline weight, run-in design, and analysis conventions.
That two-point cross-trial drift is roughly two-thirds the size of the entire benefit STEP UP measured from tripling the semaglutide dose. Any arithmetic that subtracts one trial's number from another's inherits that noise. No randomized trial has yet compared tirzepatide directly against semaglutide 7.2 mg, so the honest statement today is that the dose-matched gap between the two compounds is unknown — narrower than the ad campaigns imply, and not established as zero.
The higher dose also carries a tolerability cost that the headline percentage hides. In STEP UP, gastrointestinal adverse events occurred in 70.8% of the 7.2 mg group versus 61.2% at 2.4 mg, and dysaesthesia — altered or tingling sensation — was reported by 22.9% at 7.2 mg versus 6.0% at 2.4 mg and 0.5% on placebo. Serious adverse events were 6.8% at 7.2 mg and 10.9% at 2.4 mg. A similar tingling signal has been reported in the retatrutide dysesthesia data, suggesting it tracks with dose intensity across the class rather than with any one compound.
What this changes for people comparing the two compounds
For anyone weighing semaglutide against tirzepatide, the practical takeaway is narrow but real: the widely circulated "tirzepatide produces about 50% more weight loss" framing is a statement about specific doses in a specific trial, not a property of the molecules. It was accurate for the doses SURMOUNT-5 tested. It is not automatically portable to the dose range now approved.
Our own semaglutide vs tirzepatide comparison breaks down the head-to-head evidence, and the tirzepatide lean-mass analysis covers a separate trade-off in body composition that percentage-of-bodyweight figures do not capture on either side.
Nothing in this case touches the research-use-only market. It is an advertising dispute between two manufacturers over branded campaigns, and it does not change the regulatory status, availability, or pricing of research-grade material. Current per-mg pricing and COA documentation by vendor are listed on the semaglutide and tirzepatide pages, and active vendor codes are on the deals page.
